JP2020536501A - 遺伝子発現調節のための人為的なゲノム操作 - Google Patents
遺伝子発現調節のための人為的なゲノム操作 Download PDFInfo
- Publication number
- JP2020536501A JP2020536501A JP2020513755A JP2020513755A JP2020536501A JP 2020536501 A JP2020536501 A JP 2020536501A JP 2020513755 A JP2020513755 A JP 2020513755A JP 2020513755 A JP2020513755 A JP 2020513755A JP 2020536501 A JP2020536501 A JP 2020536501A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- sequence
- nucleic acid
- domain
- here
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021170086A JP7440043B2 (ja) | 2017-09-28 | 2021-10-18 | 遺伝子発現調節のための人為的なゲノム操作 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564478P | 2017-09-28 | 2017-09-28 | |
| US62/564,478 | 2017-09-28 | ||
| US201762565868P | 2017-09-29 | 2017-09-29 | |
| US62/565,868 | 2017-09-29 | ||
| PCT/KR2018/011424 WO2019066490A2 (ko) | 2017-09-28 | 2018-09-27 | 유전자 발현 조절을 위한 인위적인 게놈 조작 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021170086A Division JP7440043B2 (ja) | 2017-09-28 | 2021-10-18 | 遺伝子発現調節のための人為的なゲノム操作 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2020536501A true JP2020536501A (ja) | 2020-12-17 |
Family
ID=65902054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513755A Pending JP2020536501A (ja) | 2017-09-28 | 2018-09-27 | 遺伝子発現調節のための人為的なゲノム操作 |
| JP2021170086A Active JP7440043B2 (ja) | 2017-09-28 | 2021-10-18 | 遺伝子発現調節のための人為的なゲノム操作 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021170086A Active JP7440043B2 (ja) | 2017-09-28 | 2021-10-18 | 遺伝子発現調節のための人為的なゲノム操作 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3690047A4 (https=) |
| JP (2) | JP2020536501A (https=) |
| KR (1) | KR102670361B1 (https=) |
| CN (2) | CN118581083A (https=) |
| AU (1) | AU2018339164B2 (https=) |
| BR (1) | BR112020006428A2 (https=) |
| RU (2) | RU2767201C2 (https=) |
| SG (1) | SG11202002130WA (https=) |
| WO (1) | WO2019066490A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025079278A1 (ja) * | 2023-10-10 | 2025-04-17 | 国立大学法人 東京医科歯科大学 | シャルコー・マリー・トゥース病の処置剤 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110577969B (zh) * | 2019-08-08 | 2022-07-22 | 复旦大学 | CRISPR/Sa-SlugCas9基因编辑系统及其应用 |
| CN110577970B (zh) * | 2019-08-08 | 2022-11-18 | 复旦大学 | CRISPR/Sa-SlutCas9基因编辑系统及其应用 |
| CN110577972B (zh) * | 2019-08-08 | 2022-10-11 | 复旦大学 | CRISPR/Sa-ShaCas9基因编辑系统及其应用 |
| EP4091635A4 (en) * | 2020-01-14 | 2024-02-21 | Toolgen Incorporated | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALZHEIMER'S DISEASE AND USE THEREOF |
| AU2021390471A1 (en) * | 2020-12-01 | 2023-06-29 | Research Institute At Nationwide Children's Hospital | Products and methods for inhibition of expression of peripheral myelin protein-22 |
| US12516347B2 (en) | 2021-02-02 | 2026-01-06 | Limagrain Europe | Linkage of a distal promoter to a gene of interest by gene editing to modify gene expression |
| CN114426982B (zh) * | 2022-02-22 | 2024-03-22 | 上海交通大学 | 一种细胞代谢重编程的方法及其应用 |
| WO2024053964A1 (ko) * | 2022-09-06 | 2024-03-14 | 주식회사 툴젠 | 캄필로박터 제주니 유래 cas9의 가이드 rna 구조변화를 통한 유전자교정 향상 시스템 |
| CN116536357A (zh) * | 2023-04-17 | 2023-08-04 | 中国医学科学院输血研究所 | 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4357457B1 (en) * | 2012-10-23 | 2024-10-16 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| CN105121648B (zh) * | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| SI2986729T1 (sl) * | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| KR20160019553A (ko) | 2013-06-17 | 2016-02-19 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| US9388430B2 (en) * | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| WO2015048577A2 (en) * | 2013-09-27 | 2015-04-02 | Editas Medicine, Inc. | Crispr-related methods and compositions |
| BR112016013207A2 (pt) * | 2013-12-12 | 2017-09-26 | Massachusetts Inst Technology | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais |
| EP3341727B1 (en) * | 2015-08-25 | 2022-08-10 | Duke University | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases |
| WO2017053431A2 (en) | 2015-09-21 | 2017-03-30 | Arcturus Therapeutics, Inc. | Allele selective gene editing and uses thereof |
| ES2905558T3 (es) * | 2015-11-13 | 2022-04-11 | Avellino Lab Usa Inc | Procedimientos para el tratamiento de las distrofias corneales |
| WO2018088694A2 (ko) * | 2016-11-14 | 2018-05-17 | 주식회사 툴젠 | 인위적으로 조작된 sc 기능 조절 시스템 |
| JP7416406B2 (ja) * | 2016-12-08 | 2024-01-17 | ケース ウェスタン リザーブ ユニバーシティ | 機能的ミエリン産生を増進させるための方法および組成物 |
-
2018
- 2018-09-27 SG SG11202002130WA patent/SG11202002130WA/en unknown
- 2018-09-27 WO PCT/KR2018/011424 patent/WO2019066490A2/ko not_active Ceased
- 2018-09-27 JP JP2020513755A patent/JP2020536501A/ja active Pending
- 2018-09-27 CN CN202410521102.1A patent/CN118581083A/zh active Pending
- 2018-09-27 KR KR1020180114900A patent/KR102670361B1/ko active Active
- 2018-09-27 AU AU2018339164A patent/AU2018339164B2/en active Active
- 2018-09-27 RU RU2020114785A patent/RU2767201C2/ru active
- 2018-09-27 RU RU2022103641A patent/RU2022103641A/ru unknown
- 2018-09-27 BR BR112020006428-9A patent/BR112020006428A2/pt not_active Application Discontinuation
- 2018-09-27 EP EP18862957.0A patent/EP3690047A4/en active Pending
- 2018-09-27 CN CN201880076752.2A patent/CN111527208B/zh active Active
-
2021
- 2021-10-18 JP JP2021170086A patent/JP7440043B2/ja active Active
Non-Patent Citations (6)
| Title |
|---|
| "A Genome Editing Approach to Studying Pmp22 Enhancer Functionality", FASEB JOURNAL, vol. 30, no. 1, JPN7021001669, 2016, pages 584 - 2, ISSN: 0004888104 * |
| CELL, vol. vol.159, p.647-661, JPN6022007791, 2014, ISSN: 0004716727 * |
| JBC, vol. 269, no. 41, JPN6021017555, 1994, pages 25795 - 25808, ISSN: 0004888100 * |
| NATURE BIOTECHNOLOGY, vol. vol.32, p.279-284, JPN6022007789, 2014, ISSN: 0004716726 * |
| NATURE, vol. vol.516, p.263-266, JPN6022007788, 2014, ISSN: 0004716725 * |
| RENNOLL, SHERRI A. ET AL., CANCERS, vol. 8, no. 52, JPN6021017551, 2016, pages 1 - 15, ISSN: 0004888099 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025079278A1 (ja) * | 2023-10-10 | 2025-04-17 | 国立大学法人 東京医科歯科大学 | シャルコー・マリー・トゥース病の処置剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118581083A (zh) | 2024-09-03 |
| JP2022023144A (ja) | 2022-02-07 |
| BR112020006428A2 (pt) | 2020-09-24 |
| WO2019066490A3 (ko) | 2019-06-27 |
| EP3690047A4 (en) | 2021-11-03 |
| RU2767201C2 (ru) | 2022-03-16 |
| CN111527208B (zh) | 2024-05-14 |
| KR102670361B1 (ko) | 2024-05-29 |
| RU2022103641A (ru) | 2022-03-18 |
| EP3690047A2 (en) | 2020-08-05 |
| CA3077153A1 (en) | 2019-04-04 |
| RU2020114785A (ru) | 2021-10-28 |
| KR20190037145A (ko) | 2019-04-05 |
| CN111527208A (zh) | 2020-08-11 |
| AU2018339164B2 (en) | 2022-06-16 |
| RU2020114785A3 (https=) | 2021-10-28 |
| WO2019066490A2 (ko) | 2019-04-04 |
| SG11202002130WA (en) | 2020-04-29 |
| AU2018339164A1 (en) | 2020-04-09 |
| JP7440043B2 (ja) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7440043B2 (ja) | 遺伝子発現調節のための人為的なゲノム操作 | |
| KR102621539B1 (ko) | 인위적으로 조작된 sc 기능 조절 시스템 | |
| CN109844123A (zh) | 经人工操纵的血管生成调控系统 | |
| KR20160023765A (ko) | Rna-가이드 유전자 편집 및 유전자 조절 | |
| JP2020500537A (ja) | 機能的ミエリン産生を増進させるための方法および組成物 | |
| Liu et al. | Allele-specific gene-editing approach for vision loss restoration in RHO-associated retinitis pigmentosa | |
| US12163149B2 (en) | Artificial genome manipulation for gene expression regulation | |
| JP2020528735A (ja) | 反復伸長変異のためのゲノム編集システム | |
| CA3077153C (en) | Artificial genome manipulation for gene expression regulation | |
| HK40035616B (zh) | 用於基因表逹调节的人工基因组操纵 | |
| CA3043148C (en) | Artificially engineered sc function control system | |
| HK40035616A (en) | Artificial genome manipultation for gene expression regulation | |
| Croci | CRISPR-Cas9 gene editing: a new promising treatment for Rett syndrome | |
| HK40014170A (en) | Artificially engineered sc function control system | |
| HK40014170B (zh) | 经人工操纵的sc功能控制系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200409 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200409 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210518 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210818 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211018 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220301 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20221004 |